We read the interim analysis from the REGARD study, in which the Chari et al1 used laboratory glycemic data to define glycemically defined new-onset diabetes (GNOD) in adults aged 50 years of age and older and then quantified the 3-year risk of pancreatic cancer. This work anchors risk on a clear timeline and offers real-world evidence for using GNOD as an entry point for early detection. A few signals, however, could be brought to the foreground to make bedside risk discussions and downstream trial design more straightforward.
We read the interim analysis from the REGARD study, in which the Chari et al1 used laboratory glycemic data to define glycemically defined new-onset diabetes (GNOD) in adults aged 50 years of age and older and then quantified the 3-year risk of pancreatic cancer. This work anchors risk on a clear timeline and offers real-world evidence for using GNOD as an entry point for early detection. A few signals, however, could be brought to the foreground to make bedside risk discussions and downstream trial design more straightforward.